As the world anxiously awaits news of a COVID-19 vaccine, a new study offers some hope. Researchers found that people who received two doses of CoronaVac, an mRNA vaccine, had a better antibody response when they were given a booster dose of the vaccine.
The study, which is still preliminary, was conducted on healthy adults in Brazil. All of the participants received two doses of CoronaVac, 21 days apart. Then, six weeks after the second dose, they received a booster dose of either CoronaVac or a different vaccine.
The researchers found that the booster dose of CoronaVac improved the antibody response in people who had received two doses of the vaccine. This is encouraging news, as it suggests that people who have been vaccinated with CoronaVac may have a better protection against the virus if they receive a booster dose.
The study is still ongoing, and more research is needed to confirm the findings. However, the results offer a glimmer of hope that a COVID-19 vaccine may be able to provide better protection against the virus.
mRNA vaccines are a new type of vaccine that offer a more broad range of protection against infections. A new study suggests that people who receive two doses of an mRNA vaccine, such as the one developed by Pfizer/BioNTech, have a better response to the infection than those who receive one dose.
The findings, published in the journal Science, suggest that the double-dose vaccine is more effective at protecting against both severe and mild disease. The study also found that the vaccine is safe and well-tolerated.
The findings are based on a clinical trial of 1,600 people in Brazil. Participants were randomly assigned to receive either one or two doses of the CoronaVac vaccine, a vaccine developed by the Chinese company Sinovac.
The trial found that the vaccine was 60% effective at preventing symptomatic disease, and 100% effective at preventing severe disease. Among those who received two doses, the vaccine was 85% effective at preventing symptomatic disease.
The researchers say the findings suggest that the two-dose vaccine is more effective at protecting against both severe and mild disease. However, they noted that the trial was conducted in a small number of people and more research is needed to confirm the findings.
The findings come as countries around the world are grappling with how to best use their limited supplies of vaccines. In general, experts have recommended that countries focus on vaccinating health care workers and people at high risk of severe disease first.
However, the new study suggests that vaccinating a larger number of people with a two-dose vaccine may be more effective at reducing the overall burden of disease. The findings add to the growing body of evidence that suggests that two doses of an mRNA vaccine offer better protection against COVID-19 than one dose.
